MYND Life Sciences Inc.
MYND
CNSX
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -44.80% | 30.71% | -179.94% | 186.81% | 12.74% |
| Total Depreciation and Amortization | -80.00% | 0.00% | -28.57% | 0.00% | -87.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.50% | -- | -- | -572.44% | -1.70% |
| Change in Net Operating Assets | 51.96% | -33.82% | -15.57% | 48.70% | -33.00% |
| Cash from Operations | -103.07% | 203.17% | 77.71% | -234.38% | -537.93% |
| Capital Expenditure | 200.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -200.00% | -- | -- | -- | 100.00% |
| Cash from Investing | -- | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -198.13% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.40% | 203.52% | -28,500.00% | 116.67% | -146.15% |